Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 9/20 | 1.00 |
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.78 |
| ▸ | XDH | P47989 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571576 | 0.91 | XDH (0.84) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30527861 | 0.90 | MAPT (0.82) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5504492 | 0.90 | MAPT (0.82) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29068825 | 0.89 | MAPT (0.80) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1742372 | 0.88 | PIN1 (1.00) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5814089 | 0.87 | XDH (0.78) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13774686 | 0.86 | XDH (0.76) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| Isoformonentin SCHEMBL73338 | 0.86 | XDH (1.00) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12289033 | 0.86 | XDH (0.76) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22340136 | 0.86 | XDH (0.76) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| CN-119654404-A | Methods and compositions for producing oligodendrocyte progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| EP-4444870-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118382694-A | Methods and compositions for generating human erythroid progenitors | 特雷尔赫德生物系统股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| WO-2024063818-A9 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024076758-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-04-11 | — | — | WO | claimed |
| US-20240117302-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024063818-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-03-28 | — | — | WO | claimed |
| US-20240043798-A1 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-02-08 | — | — | US | claimed |
| US-11596657-B2 | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2023-03-07 | — | — | US | claimed |
| CN-112716934-A | Application of 7-methoxyisoflavone in endothelial inflammation | 华中科技大学同济医学院附属协和医院 | 2021-04-30 | — | — | CN | claimed |
| CN-109674781-B | Application of 7-methoxyisoflavone in preparing medicine for treating allergic diseases and autoimmune diseases | 中国药科大学 | 2021-03-12 | — | — | CN | claimed |
| US-20190282638-A1 | USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2019-09-19 | — | — | US | claimed |
| EP-3522902-A1 | USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS | Institut National de la Recherche Agronomique (FR) | 2019-08-14 | — | — | EP | claimed |
| CN-109674781-A | Application of 7-methoxyisoflavone in preparing medicine for treating allergic diseases and autoimmune diseases | 中国药科大学 | 2019-04-26 | — | — | CN | claimed |
| WO-2018065132-A1 | USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS. | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2018-04-12 | — | — | WO | claimed |
| CN-101591324-B | Three crystal forms of 5-methyl-7-methoxyisoflavone, preparation method thereof, pharmaceutical composition thereof and application thereof | INST MATERIA MEDICA CAMS | 2013-07-10 | — | — | CN | claimed |
| CN-101591324-A | Three crystal forms of 5-methyl-7-methoxyisoflavone, preparation method thereof, pharmaceutical composition thereof and application thereof | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | claimed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | ARG2, ARG1, OTC | MAPT 3726/4885ALDH1A1 292/4885SMN1; SMN2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.